MoonLake Immunotherapeutics (MLTX) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Omeros (OMER) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 48.9% versus a loss of 12.6%. Over five years, OMER leads with a +77.8% price change compared with +12.2% for MLTX. Omeros is the larger company by market cap ($983.7 million vs $942.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLTX | OMER |
|---|---|---|
| Share price | $11.07 | $13.21 |
| Market cap | $942.13M | $983.66M |
| 1-day change | +0.36% | -5.71% |
| YTD return | -16.01% | -23.11% |
| 1-year return | -12.63% | +48.93% |
| 5-year return | +12.16% | +77.79% |
| P/E ratio (TTM) | — | 15.92 |
| Forward P/E | — | 11.95 |
| EPS (TTM) | $-3.66 | $0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-227.32M | $-3.35M |
| 52-week high | $23.29 | $21.24 |
| 52-week low | $9.46 | $6.70 |
| Distance from 52-week high | -52.47% | -37.81% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +173.62% | +108.18% |
| Average volume | 1.64M | 1.36M |
| Shares outstanding | 85.11M | 74.46M |
| Employees | 130 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed MLTX by 61.6 percentage points over the past year.
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
MLTX vs OMER FAQ
Which is bigger, MoonLake Immunotherapeutics or Omeros?
Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $942.13M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, MLTX or OMER?
OMER returned +48.93% over the past 12 months, compared with -12.63% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are MoonLake Immunotherapeutics and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.